{
    "2018-01-19": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Cancer Space Update: Label Expansions, Data Readouts in Focus",
                "features": {
                    "keywords": [
                        "Cancer",
                        "Label Expansions",
                        "Data Readouts"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-04-10",
                "original_text": "Notable ETF Inflow Detected - VEA, NSRGY, NVS, TM",
                "features": {
                    "keywords": [
                        "ETF Inflow",
                        "VEA",
                        "NSRGY",
                        "NVS",
                        "TM"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "global equities"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-01",
                "original_text": "Pharma Stock Roundup: Merck's Keytruda Shines in Study, Priority Review for Kymriah Label Expansion",
                "features": {
                    "keywords": [
                        "Pharma",
                        "Keytruda",
                        "Kymriah",
                        "Priority Review"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-06-20",
                "original_text": "How Is Bristol-Myers Squibb’s Sprycel Positioned for 2018?",
                "features": {
                    "keywords": [
                        "Bristol-Myers Squibb",
                        "Sprycel",
                        "Positioned"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-07-12",
                "original_text": "Amgen’s Aimovig is Expected to Witness Steady Growth in 2018",
                "features": {
                    "keywords": [
                        "Amgen",
                        "Aimovig",
                        "Steady Growth"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-08-15",
                "original_text": "The Swiss Stock Market Climbed Again, But Finishes Week With A Loss",
                "features": {
                    "keywords": [
                        "Swiss Stock Market",
                        "Climbed",
                        "Loss"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "general market"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-09-25",
                "original_text": "Blog Exposure - FDA Granted Priority Review to Novartis’ Kymriah(TM) for Adults with relapsed/refractory B-cell lymphoma",
                "features": {
                    "keywords": [
                        "FDA",
                        "Priority Review",
                        "Novartis",
                        "Kymriah",
                        "Lymphoma"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-10-10",
                "original_text": "Pharma Stock Roundup: Merck's Keytruda Shines in Study, Priority Review for Kymriah Label Expansion",
                "features": {
                    "keywords": [
                        "Pharma",
                        "Keytruda",
                        "Kymriah",
                        "Priority Review"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}